Tsingzhi Cap

Tsingzhi Cap (清智资本) is a Chinese venture capital fund, but elsewhere's corpus contains no dedicated profile of it — the fund appears only as a co-investor in portfolio announcements from other GPs. In June 2022, per 5Y Capital and Gaorong's coverage, it joined the nearly RMB 500 million Series A of Helixon, an AI-powered large-molecule drug discovery company, as one of three angel-round backers following on alongside Xiang He Capital and Gaorong's GL Ventures . It also participated in humanoid robotics maker Dongyi Technology — co-investing in the tens-of-millions RMB angel round reported in September 2024, led by FreeS Fund and Zhipu's Z Fund , and leading the follow-on angel+ round that pushed Dongyi's cumulative funding past RMB 100 million by June 2025 . Based on this sparse record, its visible bets cluster around frontier tech — AI drug discovery and embodied AI — but founding date, fund size, and team are not covered in elsewhere's material.